[Low grade fibromixoid sarcoma: a purpose of 3 cases and review of the bibliography].
[Low grade fibromixoid sarcoma: a purpose of 3 cases and review of the bibliography].
BACKGROUND
Low grade fibromyxoid sarcoma or tumor Evans is a variety of soft tissue sarcoma that represents 1% of all malignancies. More common in limbs and trunk (50%), we present 3 new cases of retroperitoneal reviewing their characteristics and performing a literature review.
METHODS
In the retroperitoneal location highlights the poor specificity of clinical symptoms, demonstrating, according to their growth and size, as an abdominal tumor, usually painless, or by compression and/or invasion of nearby structures. In cases that present the most important finding was the presence of a palpable abdominal tumor without other symptoms despite remarkable infiltration of other organs that should be included in surgical resection.
CONCLUSIONS
We emphasize the difficulty of correct diagnosis preoperatively because preoperative studies are inconclusive and only the histological and immuno–histo-typing chemistry allow precise identification.
[Determination of ER-D5 (estrogen receptor related antigen) in prostatic cancer and its significance].
The existence of an estrogen receptor and various other sex steroid receptors has been confirmed in prostatic cancer. However, the action mechanism of hormone therapy and relationship between the disappearance of hormone response, which is observed in the recurrence of prostatic cancer, and various sex steroid receptors have yet to be identified. The use of monoclonal antibody ERICA is known as a method of detecting the estrogen receptor in the immuno–histological chemistry method. However, this monoclonal antibody is difficult to use on paraffin sections. Therefore, using monoclonal antibody D5, which allows ER-D5 detection of the estrogen receptor related antigen on paraffin sections, we investigated whether or not estrogen receptors are present in the prostatic cancer preparation and studied the survival rate of prostatic cancer as well as relationship with recurrence.
Positive ER-D5 results were obtained in 37 of 93 prostatic cancer cases (39.8%) and in all 20 prostatic hypertrophy cases (100%). ER-D5 tended to be more densely stained in prostatic hypertrophy than in prostatic cancer. The survival rate was obviously higher in the ER-D5 positive prostatic cancer cases than in ER-D5 negative cases for a certain period of time after the start of treatment. Despite differences in the histo-differentiation degree and clinical stage of prostatic cancer, the ER-D5 positive percentage did not change and remained between 35% and 45%. In cases where another prostatic cancer preparation was taken because of recurrence of prostatic cancer, there were no ER-D5 positive cases at the time of recurrence.(ABSTRACT TRUNCATED AT 250 WORDS)
Activation of TRPV4 channels leads to a consistent tocolytic effect on human myometrial tissues
Background: Human myometrium is a therapeutic target for labor induction and preterm labor.
Objective: This study aimed to assess the physiological role of alternative calcium conductance on contractions triggered by uterotonic drugs in human myometrium. Membrane conductances, supported by TRPV channels, may provide alternative pathways to control either free intracellular and/or submembrane Ca2+-concentration, which in turn will modulate membrane polarization and contractile responses.
Study design: Uterine biopsies were obtained from consenting women undergoing elective caesarean delivery at term without labor (N = 22). Isometric tension measurements were performed on uterine smooth muscle strips (n = 132). Amplitude, frequency, and area under the curve (AUC) of phasic contractions, as well as resting tone, were measured under various experimental conditions. Immuno histo– and cyto-chemistry, as well as Western blot analyses, have been performed with specific antibodies against TRPV1, TRPV3, and TRPV4 proteins. TRPV4 agonists; GSK1016790A, 4αPDD, and 5,6-EET were used to assess the role of TRPV4 channels on rhythmic activity triggered by 30-300 nM oxytocin. 5 μM of ruthenium red was used as an efficient blocker of ionic current through TRPV4 channels. Nanomolar concentrations of iberiotoxin (IbTX) were also used to confirm the downstream involvement of BKCa channels in controlling uterine reactivity and contractility.
Results: The expression of TRPV3 and TRPV4 isoforms has now been demonstrated in human myometrial tissue and cell culture. Nanomolar concentrations of the TRPV4 agonists, (either GSK1016790A or 4αPDD) abolished the rhythmic contractions, resulting in a rapid and consistent tocolytic effect. While 5 μM of ruthenium reversed this tocolytic effect. The addition of IbTX (a BKCa channel blocker) reversed the effects of GSK1016790A. Carvacrol, a TRPV3 agonist, had similar tocolytic effects on rhythmic contractions albeit at higher concentrations. This inhibitory effect was also reversed by ruthenium red.
Conclusion: Collectively, these data suggest that activation of TRPV4 leads to a Ca2+ entry and subsequent BKCa channel activation (increase in open state probability), which in turn hyperpolarizes the myometrial cell membrane, inactivating L-type Ca2+ channels and efficiently abrogates contractile activity. Consequently, alternative Ca2+ conductance supported by TRPV4 plays a physiological role in the modulation of myometrial reactivity.
The real-time polymerase chain reaction.
The scientific, medical, and diagnostic communities have been presented the most powerful tool for quantitative nucleic acids analysis: real-time PCR [Bustin, S.A., 2004. A-Z of Quantitative PCR. IUL Press, San Diego, CA]. This new technique is a refinement of the original Polymerase Chain Reaction (PCR) developed by Kary Mullis and coworkers in the mid 80:ies [Saiki, R.K., et al., 1985. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia, Science 230, 1350], for which Kary Mullis was awarded the 1993 year’s Nobel prize in Chemistry.
 Genorise® recombinant Bovine GM-CSF protein |
|||
| GR120027 | Genorise Scientific | 5 µg | EUR 285 |
 Bovine GM-CSF Antibody |
|||
| GWB-592EC9 | GenWay Biotech | 0.5 mg | Ask for price |
 GM CSF Recombinant Protein |
|||
| 96-356 | ProSci | 0.02 mg | EUR 500.1 |
|
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is also known as Colony stimulating factor 2 (granulocyte-macrophage), is a cytokine initially characterized by its ability to induce colonies of granulocytes and macrophages from myeloid progenitor cells, and is secreted by macrophages, T cells, mast cells, endothelial cells and fibroblasts. GM-CSF is a cytokine that functions as a white blood cell growth factor. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Monocytes exitthe circulation and migrate into tissue, whereupon they mature into macrophages and dendritic cells. Thus, it is part of the immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection. The active form of the protein is found extracellularly as a homodimer. Human GM-CSF glycosylated in its mature form. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has also recently been evaluated in clinical trials for its potential as a vaccine adjuvant in HIV-infected patients. The preliminary results have been promising. GM-CSF is also used as a medication to stimulate the production of white blood cells following chemotherapy. |
|||
 Recombinant Human CSF-2/GM-CSF Protein |
|||
| RP02372 | Abclonal | 100μg | EUR 244.43 |
 Bovine GM-CSF ELISA Kit |
|||
| EBG0023 | Abclonal | 96Tests | EUR 625.2 |
Bovine GM-CSF ELISA Kit |
|||
| EBG0342 | Abclonal | 96Tests | EUR 625.2 |
Bovine GM-CSF ELISA Kit |
|||
| ELA-E0045b | Nova Lifetech | 96tests | EUR 796 |
 Mouse Anti Bovine GM-CSF |
|||
| MBS225634-01mg | MyBiosource | 0.1mg | EUR 425 |
Mouse Anti Bovine GM-CSF |
|||
| MBS225634-5x01mg | MyBiosource | 5x0.1mg | EUR 1745 |
 RABBIT ANTI BOVINE GM-CSF |
|||
| MBS225882-01mg | MyBiosource | 0.1mg | EUR 645 |
RABBIT ANTI BOVINE GM-CSF |
|||
| MBS225882-5x01mg | MyBiosource | 5x0.1mg | EUR 2730 |
 Recombinant Mouse GM-CSF/CSF2 |
|||
| AP76135 | SAB | 1mg | EUR 3489 |
Recombinant Mouse GM-CSF/CSF2 |
|||
| CK02-10ug | Novoprotein | 10ug | EUR 242.4 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB,150mM NaCl, pH7.4. |
|||
Recombinant Mouse GM-CSF/CSF2 |
|||
| CK02-1mg | Novoprotein | 1mg | EUR 2983.2 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB,150mM NaCl, pH7.4. |
|||
Recombinant Mouse GM-CSF/CSF2 |
|||
| CK02-500ug | Novoprotein | 500ug | EUR 1935.6 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB,150mM NaCl, pH7.4. |
|||
Recombinant Mouse GM-CSF/CSF2 |
|||
| CK02-50ug | Novoprotein | 50ug | EUR 595.2 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB,150mM NaCl, pH7.4. |
|||
) Recombinant Human GM-CSF (CSF2) |
|||
| Z100275 | ABM | 20 µg | EUR 85 |
|
Description: GM-CSF is a hematopoietic growth factor that is produced by endothelial cells, monocytes, fibroblasts and T-lymphocytes following their activation by antigens or mitogens. GM-CSF stimulates the development of macrophages and neutrophils and plays a role in the proliferation and development of early erythroid megakaryocytic and eosinophilic progenitor cells. Approximately 90% of the secreted colony stimulating activities are due to GM-CSF. While non-glycosylated and glycosylated GM-CSF show similar activities in vitro, fully glycosylated GM-CSF is biologically more active in vivo compared to its non-glycosylated counterpart. Human and murine GM-CSF are species-specific and therefore, exhibit no cross-reactivity. Recombinant Human GM-CSF is a non-glycosylated, monomeric protein that contains intra-chain disulfide bonds. |
|||
Recombinant Human GM-CSF (CSF2) |
|||
| Z100277 | ABM | 100 µg | EUR 210 |
|
Description: GM-CSF is a hematopoietic growth factor that is produced by endothelial cells, monocytes, fibroblasts and T-lymphocytes following their activation by antigens or mitogens. GM-CSF stimulates the development of macrophages and neutrophils and plays a role in the proliferation and development of early erythroid megakaryocytic and eosinophilic progenitor cells. Approximately 90% of the secreted colony stimulating activities are due to GM-CSF. While non-glycosylated and glycosylated GM-CSF show similar activities in vitro, fully glycosylated GM-CSF is biologically more active in vivo compared to its non-glycosylated counterpart. Human and murine GM-CSF are species-specific and therefore, exhibit no cross-reactivity. Recombinant Human GM-CSF is a non-glycosylated, monomeric protein that contains intra-chain disulfide bonds. |
|||
Recombinant Human GM-CSF (CSF2) |
|||
| Z100279 | ABM | 10 x 100 µg (Z100277 x 10) | EUR 1980 |
|
Description: GM-CSF is a monomeric protein of 127 amino acids with two glycosylation sites. The protein is synthesized as a precursor of 144 amino acids, which included a hydrophobic secretory signal sequence at the amino terminal end. The sugar moiety is not required for the full spectrum of biological activities. Non-glycosylated and glycosylated GM-CSF show the same activities in vitro. Fully glycosylated GM-CSF is biologically more active in vivo than the non-glycosylated protein. This protein is secreted together with other factors by T cells and macrophages following cell activation by antigens or mitogens. Approximately 90% of the secreted colony stimulating activities are due to GM-CSF. |
|||
) Recombinant Mouse GM-CSF (CSF2) |
|||
| Z200075 | ABM | 20 µg | EUR 190 |
|
Description: GM-CSF is a monomeric cytokine with two glycosylation sites that stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes. CSF2 is secreted together with other factors by T cells and macrophages following cell activation by antigens or mitogens. The signalling ‘GM-CSF:receptor’ complex is a dodecamer of two hexamers of two alpha, two beta, and two ligand subunits. While non-glycosylated and glycosylated GM-CSF show similar activities in vitro, fully glycosylated GM-CSF is biologically more active in vivo. Recombinant Mouse CSF2 is a non-glycosylated, monomeric protein. |
|||
Recombinant Mouse GM-CSF (CSF2) |
|||
| Z200077 | ABM | 5 x 20 µg (Z200075 x 5) | EUR 850 |
|
Description: GM-CSF is a monomeric cytokine with two glycosylation sites that stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes. CSF2 is secreted together with other factors by T cells and macrophages following cell activation by antigens or mitogens. The signalling ‘GM-CSF:receptor’ complex is a dodecamer of two hexamers of two alpha, two beta, and two ligand subunits. While non-glycosylated and glycosylated GM-CSF show similar activities in vitro, fully glycosylated GM-CSF is biologically more active in vivo. Recombinant Mouse CSF2 is a non-glycosylated, monomeric protein. |
|||
Recombinant Mouse GM-CSF (CSF2) |
|||
| Z200079 | ABM | 1.0 mg | EUR 4350 |
|
Description: GM-CSF is a monomeric protein of 127 amino acids with two glycosylation sites. The protein is synthesized as a precursor of 144 amino acids, which included a hydrophobic secretory signal sequence at the aminoterminal end. The sugar moiety is not required for the full spectrum of biological activities. Non-glycosylated and glycosylated GM-CSF show the same activities in vitro. Fully glycosylated GM-CSF is biologically more active in vivo than the non- glycosylated protein. This protein is secreted together with other factors by T cells and macrophages following cell activation by antigens or mitogens. Approximately 90% of the secreted colony stimulating activities are due to GM-CSF. |
|||
Recombinant Human GM-CSF (CSF2) |
|||
| MBS4159657-002mg | MyBiosource | 0.02mg | EUR 230 |
Recombinant Human GM-CSF (CSF2) |
|||
| MBS4159657-01mg | MyBiosource | 0.1mg | EUR 360 |
Recombinant Human GM-CSF (CSF2) |
|||
| MBS4159657-10x01mg | MyBiosource | 10x0.1mg | EUR 2405 |
Recombinant Mouse GM-CSF (CSF2) |
|||
| MBS4159924-002mg | MyBiosource | 0.02mg | EUR 340 |
Recombinant Mouse GM-CSF (CSF2) |
|||
| MBS4159924-1mg | MyBiosource | 1mg | EUR 5115 |
Recombinant Mouse GM-CSF (CSF2) |
|||
| MBS4159924-5x002mg | MyBiosource | 5x0.02mg | EUR 1100 |
Recombinant Mouse GM-CSF (CSF2) |
|||
| MBS4159924-5x1mg | MyBiosource | 5x1mg | EUR 22780 |
 Recombinant Human GM-CSF/CSF2 |
|||
| PH2025-.01 | ApexBio | 10ug | EUR 208 |
|
Description: Peptides & Proteins|Recombinant Proteins |
|||
Recombinant Human GM-CSF/CSF2 |
|||
| PH2025-.1 | ApexBio | 10X10ug | EUR 755.2 |
|
Description: Peptides & Proteins|Recombinant Proteins |
|||
)) Granulocyte Macrophage Colony Stimulating Factor, Recombinant, Bovine (GM-CSF, GMCSF, CSF, Colony Stimulating Factor, CSF2, Colony Stimulating Factor 2 (Granulocyte-Macrophage)) |
|||
| MBS650402-1mL | MyBiosource | 1mL | EUR 715 |
Granulocyte Macrophage Colony Stimulating Factor, Recombinant, Bovine (GM-CSF, GMCSF, CSF, Colony Stimulating Factor, CSF2, Colony Stimulating Factor 2 (Granulocyte-Macrophage)) |
|||
| MBS650402-5x1mL | MyBiosource | 5x1mL | EUR 3075 |
 Active Recombinant Rat CSF-2/GM-CSF Protein |
|||
| RP01207 | Abclonal | 5 μg | EUR 195 |
 Active Recombinant Human CSF-2/GM-CSF Protein |
|||
| RP00094 | Abclonal | 5 μg | EUR 39 |
 Active Recombinant Mouse CSF-2/GM-CSF Protein |
|||
| RP01206 | Abclonal | 5 μg | EUR 58.5 |
 Genorise® recombinant Bovine M-CSF protein |
|||
| GR120033 | Genorise Scientific | 5 µg | EUR 285 |
 Genorise® recombinant Bovine G-CSF protein |
|||
| GR120034 | Genorise Scientific | 5 µg | EUR 285 |
 Recombinant Rat GM-CSF/CSF2 Protein |
|||
| MBS9144114-0005mg | MyBiosource | 0.005mg | EUR 140 |
Recombinant Rat GM-CSF/CSF2 Protein |
|||
| MBS9144114-002mg | MyBiosource | 0.02mg | EUR 190 |
Recombinant Rat GM-CSF/CSF2 Protein |
|||
| MBS9144114-005mg | MyBiosource | 0.05mg | EUR 260 |
Recombinant Rat GM-CSF/CSF2 Protein |
|||
| MBS9144114-01mg | MyBiosource | 0.1mg | EUR 360 |
Recombinant Rat GM-CSF/CSF2 Protein |
|||
| MBS9144114-5x01mg | MyBiosource | 5x0.1mg | EUR 1445 |
Recombinant Rat GM-CSF/CSF2 Protein |
|||
| RP00576 | Abclonal | 50μg | EUR 49.6 |
 Recombinant Mouse GM-CSF/CSF2 Protein |
|||
| MBS9144113-002mg | MyBiosource | 0.02mg | EUR 190 |
Recombinant Mouse GM-CSF/CSF2 Protein |
|||
| MBS9144113-005mg | MyBiosource | 0.05mg | EUR 260 |
Recombinant Mouse GM-CSF/CSF2 Protein |
|||
| MBS9144113-01mg | MyBiosource | 0.1mg | EUR 360 |
Recombinant Mouse GM-CSF/CSF2 Protein |
|||
| MBS9144113-5x01mg | MyBiosource | 5x0.1mg | EUR 1445 |
 Recombinant Human GM-CSF/CSF2 Protein |
|||
| MBS9139691-0005mg | MyBiosource | 0.005mg | EUR 140 |
Recombinant Human GM-CSF/CSF2 Protein |
|||
| MBS9139691-002mg | MyBiosource | 0.02mg | EUR 190 |
Recombinant Human GM-CSF/CSF2 Protein |
|||
| MBS9139691-005mg | MyBiosource | 0.05mg | EUR 235 |
Recombinant Human GM-CSF/CSF2 Protein |
|||
| MBS9139691-01mg | MyBiosource | 0.1mg | EUR 315 |
Recombinant Human GM-CSF/CSF2 Protein |
|||
| MBS9139691-5x01mg | MyBiosource | 5x0.1mg | EUR 1235 |
Recombinant Mouse GM-CSF/CSF2 Protein |
|||
| MBS2553508-002mg | MyBiosource | 0.02mg | EUR 270 |
Recombinant Mouse GM-CSF/CSF2 Protein |
|||
| MBS2553508-01mg | MyBiosource | 0.1mg | EUR 690 |
Recombinant Mouse GM-CSF/CSF2 Protein |
|||
| MBS2553508-5x01mg | MyBiosource | 5x0.1mg | EUR 3105 |
Recombinant Human GM-CSF/CSF2 Protein |
|||
| MBS2552278-002mg | MyBiosource | 0.02mg | EUR 295 |
Recombinant Human GM-CSF/CSF2 Protein |
|||
| MBS2552278-5x002mg | MyBiosource | 5x0.02mg | EUR 1320 |
Recombinant Human GM-CSF/CSF2 Protein |
|||
| MBS2552732-001mg | MyBiosource | 0.01mg | EUR 180 |
Recombinant Human GM-CSF/CSF2 Protein |
|||
| MBS2552732-005mg | MyBiosource | 0.05mg | EUR 380 |
Recombinant Human GM-CSF/CSF2 Protein |
|||
| MBS2552732-5x005mg | MyBiosource | 5x0.05mg | EUR 1690 |
Recombinant Human GM-CSF/CSF2 Protein |
|||
| MBS2557271-002mg | MyBiosource | 0.02mg | EUR 270 |
Recombinant Human GM-CSF/CSF2 Protein |
|||
| MBS2557271-01mg | MyBiosource | 0.1mg | EUR 690 |
Recombinant Human GM-CSF/CSF2 Protein |
|||
| MBS2557271-5x01mg | MyBiosource | 5x0.1mg | EUR 3105 |
Recombinant Human GM-CSF/CSF2 Protein |
|||
| RP00473 | Abclonal | 10μg | EUR 194.84 |
Recombinant Mouse GM-CSF/CSF2 Protein |
|||
| RP00662 | Abclonal | 50μg | EUR 85.02 |
 RABBIT ANTI BOVINE GM-CSF: Biotin |
|||
| MBS225883-005mg | MyBiosource | 0.05mg | EUR 645 |
RABBIT ANTI BOVINE GM-CSF: Biotin |
|||
| MBS225883-5x005mg | MyBiosource | 5x0.05mg | EUR 2730 |
) Recombinant Human GM-CSF/CSF2 (E. coli) |
|||
| AP74770 | SAB | 1mg | EUR 2599 |
Recombinant Human GM-CSF/CSF2 (E. coli) |
|||
| C003-10ug | Novoprotein | 10ug | EUR 201.6 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, 5% Mannitol, pH 7.2. |
|||
Recombinant Human GM-CSF/CSF2 (E. coli) |
|||
| C003-1mg | Novoprotein | 1mg | EUR 2203.2 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, 5% Mannitol, pH 7.2. |
|||
Recombinant Human GM-CSF/CSF2 (E. coli) |
|||
| C003-500ug | Novoprotein | 500ug | EUR 1557.6 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, 5% Mannitol, pH 7.2. |
|||
Recombinant Human GM-CSF/CSF2 (E. coli) |
|||
| C003-50ug | Novoprotein | 50ug | EUR 486 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, 5% Mannitol, pH 7.2. |
|||
 Recombinant Bovine CSF1 Protein |
|||
| CSF1-4398B | Creative BioMart | 25 µg | EUR 498.4 |
|
Description: Store at -20 centigrade. |
|||
) Recombinant Mouse GM-CSF/CSF2 (C-6His) |
|||
| AP76095 | SAB | 1mg | EUR 3489 |
Recombinant Mouse GM-CSF/CSF2 (C-6His) |
|||
| CJ46-10ug | Novoprotein | 10ug | EUR 242.4 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB,150mM NaCl, pH7.4. |
|||
Recombinant Mouse GM-CSF/CSF2 (C-6His) |
|||
| CJ46-1mg | Novoprotein | 1mg | EUR 2983.2 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB,150mM NaCl, pH7.4. |
|||
Recombinant Mouse GM-CSF/CSF2 (C-6His) |
|||
| CJ46-500ug | Novoprotein | 500ug | EUR 1935.6 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB,150mM NaCl, pH7.4. |
|||
Recombinant Mouse GM-CSF/CSF2 (C-6His) |
|||
| CJ46-50ug | Novoprotein | 50ug | EUR 595.2 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB,150mM NaCl, pH7.4. |
|||
) Recombinant Human GM-CSF/CSF2 (P. pastoris) |
|||
| AP74796 | SAB | 1mg | EUR 2929 |
Recombinant Human GM-CSF/CSF2 (P. pastoris) |
|||
| C040-10ug | Novoprotein | 10ug | EUR 187.2 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 10mM TrisHCl, 4% Mannitol, 1% Sucrose, pH 8.5. |
|||
Recombinant Human GM-CSF/CSF2 (P. pastoris) |
|||
| C040-1mg | Novoprotein | 1mg | EUR 2496 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 10mM TrisHCl, 4% Mannitol, 1% Sucrose, pH 8.5. |
|||
Recombinant Human GM-CSF/CSF2 (P. pastoris) |
|||
| C040-500ug | Novoprotein | 500ug | EUR 1765.2 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 10mM TrisHCl, 4% Mannitol, 1% Sucrose, pH 8.5. |
|||
Recombinant Human GM-CSF/CSF2 (P. pastoris) |
|||
| C040-50ug | Novoprotein | 50ug | EUR 442.8 |
|
Description: Lyophilized from a 0.2 μm filtered solution of 10mM TrisHCl, 4% Mannitol, 1% Sucrose, pH 8.5. |
|||
 Nori® Bovine GM-CSF ELISA Kit |
|||
| GR112275 | Genorise Scientific | 96-well | EUR 461 |
) Recombinant Mouse GM-CSF/CSF2 Protein (Active) |
|||
| PKSM041031-100ug | Elabscience Biotech | 100ug | EUR 739 |
|
Description: Mouse |
|||
Recombinant Mouse GM-CSF/CSF2 Protein (Active) |
|||
| PKSM041031-20ug | Elabscience Biotech | 20ug | EUR 249 |
|
Description: Mouse |
|||
, partial) Recombinant Bovine herpesvirus 1.1 Envelope glycoprotein M (gM), partial |
|||
| MBS1148314-1mgEColi | MyBiosource | 1mg(E-Coli) | EUR 2175 |
Recombinant Bovine herpesvirus 1.1 Envelope glycoprotein M (gM), partial |
|||
| MBS1148314-1mgYeast | MyBiosource | 1mg(Yeast) | EUR 2620 |
 GM-CSF, rat recombinant |
|||
| 4102-10 | Biovision | each | EUR 307.2 |
GM-CSF, rat recombinant |
|||
| 4102-100 | Biovision | each | EUR 966 |
GM-CSF, rat recombinant |
|||
| 4102-1000 | Biovision | each | EUR 4561.2 |
GM-CSF, rat recombinant |
|||
| P1014-.1 | ApexBio | 100 µg | EUR 809 |
|
Description: GM-CSF, pleiotropic cytokine, expressed in E.Coli, active in mouse cells. |
|||
GM-CSF, rat recombinant |
|||
| P1014-1 | ApexBio | 1 mg | EUR 4017 |
|
Description: GM-CSF, pleiotropic cytokine, expressed in E.Coli, active in mouse cells. |
|||
 Recombinant Rat GM-CSF |
|||
| REOPP-0701 | Cyagen | 5ug | Ask for price |
GM-CSF, rat recombinant |
|||
| P1014-.005 | ApexBio | 5ug | EUR 108.8 |
|
Description: Growth Factors|Colony Stimulating Factor |
|||
GM-CSF, rat recombinant |
|||
| P1014-.5 | ApexBio | 500ug | EUR 2189.6 |
|
Description: Growth Factors|Colony Stimulating Factor |
|||
 Recombinant Human GM-CSF |
|||
| 6585 | Immunochemistry | 5 µg | EUR 194 |
 GM-CSF, human recombinant |
|||
| 4100-10 | Biovision | each | EUR 307.2 |
GM-CSF, human recombinant |
|||
| 4100-100 | Biovision | each | EUR 874.8 |
GM-CSF, human recombinant |
|||
| 4100-1000 | Biovision | each | EUR 3974.4 |
Recombinant Human GM-CSF |
|||
| HEOPP-0704 | Cyagen | 5ug | Ask for price |
Recombinant Human GM-CSF |
|||
| EPT108 | ELK Biotech | 500ug | EUR 1553.4 |
|
Description: Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor is produced by our Yeast expression system and the target gene encoding Ala18-Glu144 is expressed. |
|||
 Recombinant Mouse GM-CSF |
|||
| EPT161 | ELK Biotech | 50ug | EUR 491.4 |
|
Description: Recombinant Mouse Granulocyte-Macrophage Colony-Stimulating Factor is produced by our E.coli expression system and the target gene encoding Ala18-Lys141 is expressed. |
|||
 Mouse GM-CSF Recombinant |
|||
| IMSGMCSFR25UG | Innovative research | each | EUR 482 |
|
Description: Mouse GM-CSF Recombinant |
|||
Mouse GM-CSF Recombinant |
|||
| IMSGMCSFR5UG | Innovative research | each | EUR 283 |
|
Description: Mouse GM-CSF Recombinant |
|||
GM-CSF, human recombinant |
|||
| P1012-.01 | ApexBio | 10 µg | EUR 293 |
|
Description: GM-CSF, pleiotropic cytokine, species specific, expressed in E.Coli. |
|||
GM-CSF, human recombinant |
|||
| P1012-.1 | ApexBio | 100 µg | EUR 960 |
|
Description: GM-CSF, pleiotropic cytokine, species specific, expressed in E.Coli. |
|||
GM-CSF, human recombinant |
|||
| P1012-1 | ApexBio | 1 mg | EUR 4608 |
|
Description: GM-CSF, pleiotropic cytokine, species specific, expressed in E.Coli. |
|||
Recombinant Human GM-CSF |
|||
| SJA01-03 | Cusabio | 10µg/vial | EUR 342 |
Recombinant Human GM-CSF |
|||
| SJA01-04 | Amyotop | 50µg/vial | EUR 846 |
Recombinant Mouse GM-CSF |
|||
| SJF05-01 | Amyotop | 10µg/vial | EUR 307.2 |
Recombinant Mouse GM-CSF |
|||
| SJF05-02 | Amyotop | 50µg/vial | EUR 690 |
, (recombinant)) GM-CSF (human), (recombinant) |
|||
| MBS567252-01mg | MyBiosource | 0.1mg | EUR 1030 |
GM-CSF (human), (recombinant) |
|||
| MBS567252-5x01mg | MyBiosource | 5x0.1mg | EUR 4595 |
, (recombinant)) GM-CSF (mouse), (recombinant) |
|||
| MBS567253-01mg | MyBiosource | 0.1mg | EUR 1030 |
GM-CSF (mouse), (recombinant) |
|||
| MBS567253-5x01mg | MyBiosource | 5x0.1mg | EUR 4595 |
Recombinant Human GM-CSF |
|||
| MBS7615914-005mg | MyBiosource | 0.05mg | EUR 560 |
Recombinant Human GM-CSF |
|||
| MBS7615914-02mg | MyBiosource | 0.2mg | EUR 1060 |
Recombinant Human GM-CSF |
|||
| MBS7615914-1mg | MyBiosource | 1mg | EUR 3065 |